Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Galectin Therapeutics ( (GALT) ) is now available.
On September 8, 2025, Galectin Therapeutics updated its corporate presentation, highlighting the promising results of its drug Belapectin in treating MASH cirrhosis and portal hypertension. The company reported significant efficacy in reducing new varices in patients and noted encouraging responses in cancer treatments when combined with checkpoint inhibitors. The market opportunity for MASH cirrhosis is significant due to the lack of FDA-approved treatments, and Belapectin shows potential as a first- and best-in-class therapy.
The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.
Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Galectin Therapeutics is a biotechnology company focused on developing galectin-based therapeutics to improve the lives of patients with chronic liver diseases and cancer. The company is the only one exclusively targeting treatments for MASH cirrhosis and portal hypertension, with a promising drug, Belapectin, which is a galectin-3 inhibitor.
Average Trading Volume: 657,909
Technical Sentiment Signal: Buy
Current Market Cap: $294.7M
See more data about GALT stock on TipRanks’ Stock Analysis page.